Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.
Rimassa L, Dayyani F, Kelley RK, Sangro B, Chan SL, Nakamura H, Clark L, Xynos I, Abou-Alfa GK
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.